- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01271959
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
A Multicenter, Post-Market Follow-up Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
While studies support the clinical use of ChemoFx® in cancer patients, additional data are needed to further assess the utilization of this product in clinical practice. Such post-market data and information could be employed for product improvement as well as for the development of standards and regulations. This is a multicenter registry study of 3,000 patients with solid tumors. The study is not randomized, nor is it interventional in that the treating physician is free to choose how to employ ChemoFx® results in the clinical management of individual patients. Sites will be selected by Precision's clinical trials team based on past commercial usage of ChemoFx®.
Subjects who may be enrolled in this study are those who have been diagnosed with a solid tumor malignancy and for whom ChemoFx® has been ordered. ChemoFx® is ordered through the normal commercial process and is therefore billed to the patient's medical insurance.
All subjects will be appropriately consented before any study-specific data are collected. A limited dataset of patient demographics, oncology history, and therapeutic intervention will be collected in addition to ChemoFx® assay usage. Subjects will be treated based on the medical judgment of their treating physician(s). Patient survival data will be collected up to five years following the ChemoFx® commercial order. Additional disease progression data may be collected by Precision's CRAs at participating sites.
Optional Cell Research
Informed consent will be obtained to document subject's consent to use excess cells remaining in Precisions' commercial laboratory for additional research. This portion of the study may involve DNA, RNA, and proteomic research. To ensure the anonymity of each subject, any identifiers that would link the sample to the subject will be removed. The samples would then have gene expression profiling and or quantitative protein expression analysis performed. The goal of the research would be to identify a set of informative genes, intermediaries, and proteins and develop predictive algorithm(s) that seek to link the expression level of the gene, gene signature, intermediary, or protein to the clinical outcome of the patient. This portion of the study does not require any additional subject procedures. Neither physicians nor their patients will receive the results of the research performed. Results will not be placed in the subjects health care records and will not affect their medical care.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35213
- Cardio-Thoracic Surgeons, P.C.
-
-
California
-
Oakland, California, Förenta staterna, 94609
- Hematology Oncology Associates
-
-
Florida
-
Boynton Beach, Florida, Förenta staterna, 33435
- Collaborative Research Group
-
Fort Lauderdale, Florida, Förenta staterna, 33308
- Broward Oncology Associates, P.A.
-
Hollywood, Florida, Förenta staterna, 33021
- The Center For Gynecologic Oncology
-
Miami, Florida, Förenta staterna, 33143
- GYN Oncology of Miami
-
Miami, Florida, Förenta staterna, 33173
- Miami International Surgical Services
-
Orlando, Florida, Förenta staterna, 32804
- Orlando Cardiovascular Institute PA
-
-
Illinois
-
Skokie, Illinois, Förenta staterna, 60076
- Edward H. Kaplan, M.D. & Associates
-
-
Iowa
-
Des Moines, Iowa, Förenta staterna, 50309
- Iowa Clinic
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40503
- Central Baptist Hospital Clinical Research Center
-
Paducah, Kentucky, Förenta staterna, 42003
- Oncology Associates of West Kentucky
-
-
Michigan
-
Grand Blanc, Michigan, Förenta staterna, 48439
- Grand Blanc Surgical Specialist
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- Albany Thoracic & Esophageal Surgery
-
East Setauket, New York, Förenta staterna, 11733
- North Shore Hematology Oncology
-
Flushing, New York, Förenta staterna, 11355
- The New York Hospital Medical Center of Queens
-
Mineola, New York, Förenta staterna, 11501
- Winthrop University Hospital
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106
- Center for Clinical Research and Technology University Hospitals of Cleveland
-
-
Pennsylvania
-
Erie, Pennsylvania, Förenta staterna, 16505
- The Regional Cancer Center
-
-
Texas
-
Houston, Texas, Förenta staterna, 77090
- Northwest Cancer Center
-
Houston, Texas, Förenta staterna, 77054
- Colorectal Surgical Associates
-
Houston, Texas, Förenta staterna, 77024
- Barry S Siller MD
-
San Antonio, Texas, Förenta staterna, 78229
- Cancer Care Centers of South Texas
-
-
Washington
-
Spokane, Washington, Förenta staterna, 99202
- Cancer Care Northwest
-
-
West Virginia
-
Morgantown, West Virginia, Förenta staterna, 26508
- Heiskell, King, Burns & Tallman Surgical Associates, Inc.
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Pathologically confirmed diagnosis of solid tumor malignancy;
- Medically indicated to receive chemotherapy;
- Fresh tissue submitted from the solid tumor malignancy for testing with the ChemoFx® assay after August, 2006;
- Final ChemoFx® assay report is available;
- Subject must be at least 18 years of age;
- Subject must sign and date an IRB approved ICF.
Exclusion Criteria:
- Enrolled in PT-103, PT-106, PT-206, PT-301, or PT-304;
- Pregnant or lactating subjects;
- Subjects are not indicated to receive chemotherapy for their disease;
- Subjects with psychiatric or addictive disorders that would preclude obtaining informed consent.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
To determine physicians' rate of compliance with ChemoFx assay results in the treatment of subjects with solid tumors.
Tidsram: Analysis of assay-directed compliance will be conducted immediately after information is collected.
|
Analysis of assay-directed compliance will be conducted immediately after information is collected.
|
To investigate the association between the results of Precision's ChemoFx assay results and overall survival in subjects with solid tumors.
Tidsram: From date of first dose of on-study chemotherapy to date of death or last known alive.
|
From date of first dose of on-study chemotherapy to date of death or last known alive.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Karl Williams, M.D., Precision Therapeutics, Inc.
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- PT-207
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Fasta organtumörer
-
I-Mab Biopharma Co. Ltd.Inte längre tillgängligSolid Tumor Metastatic Cancer Advanced Cancer
-
National Cancer Institute (NCI)RekryteringMetastaserande Midgut Neuroendokrina Tumör | Obegreppbar Midgut Neuroendokrina Tumör | Metastatisk Midgut Neuroendocrine Tumor G1 | Metastatisk Midgut Neuroendocrine Tumor G2Förenta staterna, Kanada
-
AstraZenecaAvslutadAvancerad solid tumör | Avancerad solid malignitetJapan
-
Agenus Inc.AvslutadAvancerad solid cancer | Advanced Solid Cancers Refractory to PD-1Förenta staterna
-
Jubilant Therapeutics Inc.RekryteringMetastatisk fast tumör | Lokalt avancerad solid tumörFörenta staterna
-
Istituto Clinico HumanitasAvslutad
-
National University Hospital, SingaporeOkänd
-
Tianjin ConjuStar Biologics Co., Ltd.Rekrytering
-
China-Japan Friendship HospitalRekryteringSäkerhet och effekt av strålbehandling i kombination med immunterapi för avancerade maligna tumörer.Avancerad solid tumörKina
-
SelecxineRekryteringAvancerad solid tumörFörenta staterna, Australien, Korea, Republiken av